Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daruka Mahadevan

Showing results (11-20 of 121) with videos related to

Pageof 13
Sort By:
Expert Opinion on Investigational Drugs|March 1, 2015
Ezatiostat hydrochloride for the treatment of myelodysplastic syndromesDaruka Mahadevan, Gregory Ryan Sutton
Blood|June 26, 2004
Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategiesDaruka Mahadevan, Alan F List
Journal of Gastrointestinal Oncology|March 11, 2017
Next generation sequencing identifies 'interactome' signatures in relapsed and refractory metastatic colorectal cancerBenny Johnson, Laurence Cooke, Daruka Mahadevan
Molecular Cancer Therapeutics|April 5, 2007
Tumor-stroma interactions in pancreatic ductal adenocarcinomaDaruka Mahadevan, Daniel D Von Hoff
Expert Opinion on Investigational Drugs|December 13, 2018
Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)Sreenivasa Chandana, Hani M Babiker, Daruka Mahadevan
Current Medicinal Chemistry. Anti-Cancer Agents|April 8, 2003
Structure-based design of novel anti-cancer agents targeting aurora kinasesDaruka Mahadevan, David J Bearss, Hariprasad Vankayalapati
Neuro-Oncology Advances|March 16, 2022
Clinical trials targeting neurofibromatoses-associated tumors: a systematic reviewGabriel Roman Souza, Ahmed Abdalla, Daruka Mahadevan
Expert Opinion on Investigational Drugs|October 19, 2020
Clinical complexity of utilizing FGFR inhibitors in cancer therapeuticsSreenivasa R Chandana, Hani M Babiker, Daruka Mahadevan
Current Drug Discovery Technologies|April 14, 2007
Monoclonal antibody therapies targeting pancreatic ductal adenocarcinomaKevin Engelhardt, Christopher Riley, Laurence Cooke, et al.
Expert Opinion on Drug Discovery|May 11, 2011
Update on Aurora Kinase Targeted Therapeutics in OncologyMyke R Green, Joseph E Woolery, Daruka Mahadevan
Pageof 13

Showing results (11-20 of 121) with videos related to

Sort By:
Pageof 13
Expert Opinion on Investigational Drugs|March 1, 2015
Ezatiostat hydrochloride for the treatment of myelodysplastic syndromesDaruka Mahadevan, Gregory Ryan Sutton
Blood|June 26, 2004
Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategiesDaruka Mahadevan, Alan F List
Journal of Gastrointestinal Oncology|March 11, 2017
Next generation sequencing identifies 'interactome' signatures in relapsed and refractory metastatic colorectal cancerBenny Johnson, Laurence Cooke, Daruka Mahadevan
Molecular Cancer Therapeutics|April 5, 2007
Tumor-stroma interactions in pancreatic ductal adenocarcinomaDaruka Mahadevan, Daniel D Von Hoff
Expert Opinion on Investigational Drugs|December 13, 2018
Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)Sreenivasa Chandana, Hani M Babiker, Daruka Mahadevan
Current Medicinal Chemistry. Anti-Cancer Agents|April 8, 2003
Structure-based design of novel anti-cancer agents targeting aurora kinasesDaruka Mahadevan, David J Bearss, Hariprasad Vankayalapati
Neuro-Oncology Advances|March 16, 2022
Clinical trials targeting neurofibromatoses-associated tumors: a systematic reviewGabriel Roman Souza, Ahmed Abdalla, Daruka Mahadevan
Expert Opinion on Investigational Drugs|October 19, 2020
Clinical complexity of utilizing FGFR inhibitors in cancer therapeuticsSreenivasa R Chandana, Hani M Babiker, Daruka Mahadevan
Current Drug Discovery Technologies|April 14, 2007
Monoclonal antibody therapies targeting pancreatic ductal adenocarcinomaKevin Engelhardt, Christopher Riley, Laurence Cooke, et al.
Expert Opinion on Drug Discovery|May 11, 2011
Update on Aurora Kinase Targeted Therapeutics in OncologyMyke R Green, Joseph E Woolery, Daruka Mahadevan
Pageof 13